Drug maker Celltrion has entered into a contract manufacturing organization agreement with Baxter BioPharma Solutions for the production of its biosimilars in the United States.
Korean drug maker Celltrion has entered into a contract manufacturing organization (CMO) agreement with Baxter BioPharma Solutions for the production of its biosimilars in the United States.
Korea Biomedical Review reports that Celltrion’s contract with Baxter is intended to increase the stable supply of biosimilar products for the US marketplace. First to be produced by Baxter is Celltrion’s infliximab (Remicade) biosimilar, which has been approved by the FDA and is marketed as Inflectra in the United States. Celltrion has also submitted Biologics License Applications to the FDA for its rituximab (Rituxan, MabThera) and trastuzumab (Herceptin) biosimilars. If these 2 drugs are approved, Baxter will produce finished products of both biosimilars for the US market.
“With the latest agreement, Celltrion has secured a local drug producer in the [United States], the world’s biggest biopharmaceutical market,” a Celltrion official told The Korea Herald. “The firm expects to meet local demand in a more flexible manner.”
The news that Celltrion will manufacture Inflectra in the US follows the September release of a Form 483 issued by the FDA, noting 12 observations made while the agency inspected Celltion’s Incheon, Republic of Korea facility. Among the concerns identified were issues with vial stoppers, deficient environmental monitoring in aseptic processing areas, and inadequate procedures to prevent microbiological contamination. When the heavily redacted form was released, some analysts suggested that the FDA’s observations could be one factor in explaining the slow uptake of Inflectra in the United States.
Celltrion also recently announced that it has dropped its plans to build a third manufacturing facility in the Republic of Korea amid escalating political tensions with North Korea. Celltrion’s CEO, Seo Jun-jin, told shareholders in a September meeting that the company would make a decision concerning the location of the company’s first overseas factory by early next year.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).